

**STATEMENT BY APPLICANT**

APR 04 2005

(use as many sheets as necessary)

~~1/4~~  
Sheet

1

of

4

10/520,839

January 7, 2005

Robert J. Mathvink, et al:

100

1. *Journal of the American Medical Association*, 2000; 283: 2669-2674.

**21139YP**

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
W3	A	PCT	WO 03/082817 A2		MERCK & CO., INC.	10/09/2003
W3	B	PCT	WO 03/000180 A2		MERCK & CO., INC.	01/03/2003
W3	C	PCT	WO 03/000181 A2		MERCK & CO., INC.	01/03/2003
W3	D	PCT	WO 03/000181 A3		MERCK & CO., INC.	01/03/2003
W3	E	PCT	WO 02/076450 A1		MERCK & CO., INC.	10/03/2002
W3	F	PCT	WO 2004/007468 A1		MERCK & CO., INC.	01/22/2004
W3	G	PCT	WO 2004/032836 A2		MERCK & CO., INC.	04/22/2004
W3	H	PCT	WO 2004/050022 A2		MERCK & CO., INC.	06/17/2004
W3	I	PCT	WO 2004/058266 A1		MERCK & CO., INC.	07/15/2004
W3	J	PCT	WO 2004/064778 A2		MERCK & CO., INC.	08/05/2004

**Examiner  
Signature**

V. Balasubramanian

Date Considered

10/20/17

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

**STATEMENT BY APPLICANT**

APR 04 2005

(use as many sheets as necessary)

Sheet

2

of

4

**COMPLETELY KNOWN**

Application Number 10/530,839

<b>Filing Date</b>	January 7, 2005
--------------------	-----------------

<b>First Named Inventor</b>	<b>Robert J. Mathvink et al.</b>
-----------------------------	----------------------------------

### Group Art Unit

Examiner Name \_\_\_\_\_

Attorney Docket Number 21139YP

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
W	K	PCT	WO 2004/069162 A2		MERCK & CO., INC.	08/19/2004
W	L	PCT	WO 02/02560 A2		NOVO NORDISK A/S	01/10/2002
W	M	PCT	WO 01/96295 A2		NOVARTIS AG	12/20/2001
W	N	PCT	WO 01/96295 A3		NOVARTIS AG	12/20/2001
W	O	PCT	WO 01/34594 A1		Guilford Pharmaceuticals, Inc.	05/17/2001
W	P	PCT	WO 00/34241		NOVARTIS AG	06/15/2000
W	Q	PCT	WO 98/19998 A2		NOVARTIS AG	05/14/1998
W	R	PCT	WO 98/19998 A3		NOVARTIS AG	05/14/1998
W	S	PCT	WO 97/40832		Hansknoll-Institut Fur Naturstoff-Forschung E.V.	11/06/1997
W	T	PCT	WO 03/000180 A3		MERCK & CO., INC.	01/03/2003

**Examiner  
Signature**

V. Balazubeni

Date Considered

10/29/88

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with new communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003



Substitute for form 1449B/PTO		<b>COMPLETELY KNOWN</b>	
<b>INFORMATION DISCLOSURE</b>		Application Number	10/530,839
<b>STATEMENT BY APPLICANT</b>		Filing Date	January 7, 2005
(use as many sheets as necessary)		First Named Inventor	Robert J. Mathvink et al.
		Group Art Unit	
		Examiner Name	
Sheet 4	of 4	Attorney Docket Number	21139YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
W	A	J. J. Holst, "Treatment of Type 2 Diabetes Mellitus with Agonists of the GLP-1 Receptor or DPP-IV Inhibitors", Expert Opin. Emerg. Drugs, Vol. 9(1) pp. 155-166, 2004.
W	B	C. F. Deacon, et al., "Inhibitors of dipeptidyl peptidase IV: A Novel Approach for the Prevention and Treatment of Type 2 Diabetes?", Expert Opin. Investig. Drugs, Vol. 13(9) pp. 1091-1102, 2004.
W	C	K. Augustyns et al., "Dipeptidyl Peptidase IV Inhibitors as New Therapeutic Agents for the Treatment of Type 2 Diabetes", Expert Opin. Ther. Patents, Vol. 13(4), pp. 499-510, 2003.
W	D	Novartis AG: WO0034241, "Novel N-substituted-2-Cyanopyrrolidines as Potent Inhibitors of Dipeptidyl Peptidase IV in the Treatment of Non-Insulin-Dependent Diabetes Mellitus", Exp. Opin. Ther. Patents, Vol. 10(12), pp. 1937-1942, 2000.
W	E	O. J. Orucker, "Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes", Exp. Opin Invest. Drugs, Vol. 12, 2004, pages 87-100.
W	F	T. P. Vahl & D. A. D'Alessio, "Gut peptides in the treatment of diabetes mellitus" Exp. Opin. Invest. Drugs, Vol. 13, 2004, pages 177-188.
W	G	L. B. Knudsen, "Glucagon-like peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes", J. Med. Chem, Vol. 47, 2004, pages 4128-4134.
W	H	Ann E. Weber, "Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes", J. Med. Chem, Vol. 47, 2004, pages 4135-4141.
W	I	J. J. Holst and C. F. Deacon, "Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus", Curr. Opin Pharmacology, Vol. 4, 2004, pages 589-596.
W	J	C. F. Deacon, "Perspectives in Diabetes - Therapeutic Strategies Based on Glucagon-Like Peptide 1", Diabetes, Vol. 53, Sept. 2004, pages 2181-2189.

Examiner Signature	V. Balasubramanian	Date Considered	10/29/06
--------------------	--------------------	-----------------	----------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003